FDA.reportPublic FDA data

Anubis Barcelona

Manufacturer
ANUBIS COSMETICS SL | GDC OF FLORIDA IMPORTS, INC.
Effective date
2023-09-01
Label type
HUMAN OTC DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 23:56:03

Label at a glance#

ProductAnubis Barcelona
Active ingredientPHENOXYETHANOL, XANTHAN GUM, BENZOIC ACID, WATER, BUTYLENE GLYCOL, PROPANEDIOL, POLYSORBATE 20, EDETIC ACID, PROTEOGLYCAN 4, FRAGRANCE 13576, GLYCERIN, DEHYDROACETIC ACID
Label structure9 sections

Label contents#

Full prescribing information#

OTC - ACTIVE INGREDIENT SECTION

Proteoglycans ingredientsProteoglycans ingredients

INDICATIONS & USAGE SECTION

Proteoglycans indicationsProteoglycans indications

OTC - DO NOT USE SECTION

Proteoglycans do not useProteoglycans do not use

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Proteoglycans keepProteoglycans keep

DOSAGE & ADMINISTRATION SECTION

Proteoglycans dosageProteoglycans dosage

WARNINGS SECTION

Proteoglycans warningsProteoglycans warnings

INACTIVE INGREDIENT SECTION

Proteoglycans ingredient listProteoglycans ingredient list

OTC - PURPOSE SECTION

Proteoglycans purposeProteoglycans purpose

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Proteoglycans display panelProteoglycans display panel

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
BENZOIC ACID Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
EDETIC ACID Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813
GLYCERIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
777d68c6-a5ab-e06c-d314-677b0b9af0c8Product name220240508
c6f86816-7da6-43ea-8c25-ac9758311cc5Product name120220118
252e11b6-1a9a-4283-a242-df2c129c496dProduct name320170717

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
83021-495-20Anubis Barcelona20 mL in 1 BOTTLE, DROPPERCONCENTRATE202

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
83021-495ANUBIS BARCELONA (PROTEOGLYCAN, GLYCERIN, BUTYLENE GLYCOL) CONCENTRATE [ANUBIS COSMETICS SL]2Current NDC, Legacy NDC, 1 package rows20230902_ebdddcec-f5da-51fe-e053-2995a90a6167.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 18 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
83021-49583021-495-20

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 15 matching rows.

Name, UNII, Kind table
NameUNIIKind
PHENOXYETHANOLHIE492ZZ3TACTIB
MAGNESIUM ASCORBYL PHOSPHATE0R822556M5IACT
XANTHAN GUMTTV12P4NEEACTIB
SODIUM HYDROXIDE55X04QC32IIACT
BENZOIC ACID8SKN0B0MIMACTIB
WATER059QF0KO0RACTIB
BUTYLENE GLYCOL3XUS85K0RAACTIB
PROPANEDIOL5965N8W85TACTIB
POLYSORBATE 207T1F30V5YHACTIB
HYALURONATE SODIUMYSE9PPT4THIACT
EDETIC ACID9G34HU7RV0ACTIB
PROTEOGLYCAN 4M65IE9C8XJACTIB
FRAGRANCE 135765EM498GW35ACTIB
GLYCERINPDC6A3C0OXACTIB
DEHYDROACETIC ACID2KAG279R6RACTIB

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Anubis BarcelonaPROTEOGLYCAN, GLYCERIN, BUTYLENE GLYCOLANUBIS COSMETICS SLebdddcec-f5da-51fe-e053-2995a90a61672023-09-01WarningsExact identifier
ndc (package): 83021-495-20
ndc (product): 83021-495
ndc11 (package): 83021049520
spl id: 045289e2-7a73-8d91-e063-6394a90ab123
spl set id: ebdddcec-f5da-51fe-e053-2995a90a6167

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.